New diabetes management technology from Chesterbrook, Pa.-based Animas Corp. has been cleared by the U.S. Food and Drug Administration for the management of diabetes in adults.
The system's glucose monitoring features allows those with diabetes to view their glucose readings on the insulin pump's high-contrast color screen and to administer insulin directly from the pump. The insulin dosing also can be customized based on insulin-to-carb ratios, sensitivity factors or blood glucose targets.
Glucose readings are recorded every five minutes, and high or low glucose levels will trigger a customizable alarm. The system provides not only real-time levels but also trend information.
"For many people who are insulin dependent, diabetes is a demanding disease that can require day-to-day and hour-by-hour management," said Dr. Brian Levy, chief medical officer of Animas Corp., in a press release. "[Continuous glucose management] technology provides the ability to make more informed decisions to manage their disease, which can ultimately improve blood glucose control."